title: Clinical significance of immunogenic cell death biomarker rage and early growth response 1 in human primary gastric adenocarcinoma.
abstract: The receptor for advanced glycation end products (RAGE), a pattern recognition receptor that binds multiple ligands derived from a damaged cell environment, contributes to multiple pathologies including cancer. Early growth response 1 (EGR1) is a tumor suppressor gene or a tumor promoter involved in tumorigenesis and progression of some cancers. However, there is some lack of knowledge about the expression and clinical significance of RAGE and EGR1 in human primary gastric adenocarcinoma (GAC). The present study was aimed to investigate the expression and clinical significance of RAGE and EGR1 in human GAC. One hundred and twenty cases of GAC tissues, adjacent non-cancer tissues (ANCT) and metastatic lymph node (MLN) tissues were collected. The expression of RAGE and EGR1 was assessed using immunohistochemistry (IHC) through tissue microarray procedure. The clinicopathologic characteristics of all patients were analyzed. As a result, the expression of RAGE in GAC and MLN tissues showed the positive staining mainly in the cytoplasm, with lower reactivity rate compared with the ANCT (P less than 0.001), while EGR1 expression had no significant difference between GAC, MLN tissues and ANCT (P=0.565). Moreover, the positive expression of RAGE was closely associated with the N stage of GAC patients, but did not correlate with their age, gender, tumor size, tumor sites, T stage, and metastatic lymph node (each P>0.05). In addition, Spearman Rank correlation analysis showed the positive correlation of RAGE expression with EGR1 in GAC tissues (r=0.658). Taken together, the expression of RAGE is decreased in GAC and MLN tissues, and is associated with the N stage of GAC patients, suggesting that RAGE may represent a potential therapeutic target for the treatment of GAC.
authors.affiliation: Department of Gastrointestinal Surgery, the First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang Uygur Autonomous Region, China.
authors.forename: X-C
authors.initials: XC
authors.lastname: Xu
authors.forename: H
authors.initials: H
authors.lastname: Gao
authors.forename: W-B
authors.initials: WB
authors.lastname: Zhang
authors.forename: X
authors.initials: X
authors.lastname: Abuduhadeer
authors.forename: Y-H
authors.initials: YH
authors.lastname: Wang
mesh_terms: D000230:Adenocarcinoma / Q000737:chemistry* / Q000556:secondary; D014408:Biomarkers, Tumor / Q000032:analysis*; D001706:Biopsy; D016009:Chi-Square Distribution; D051766:Early Growth Response Protein 1 / Q000032:analysis*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008198:Lymph Nodes / Q000737:chemistry / Q000473:pathology; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic / Q000032:analysis*; D013274:Stomach Neoplasms / Q000737:chemistry* / Q000473:pathology; D046888:Tissue Array Analysis; D047368:Tumor Burden
chemical_list: D014408:Biomarkers, Tumor; C497325:EGR1 protein, human; D051766:Early Growth Response Protein 1; D000067759:Receptor for Advanced Glycation End Products; D011971:Receptors, Immunologic